CHICAGO and TORONTO, March 29, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel…
read moreCHICAGO and TORONTO, March 22, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel…
read morePre-IND Meeting is a Significant Milestone in the Clinical Development of SANA-013, Defining the Pathway to Initiate in-Human Clinical Trials in Q4 2022 CHICAGO and TORONTO, March 14, 2022 (GLOBE…
read moreNaperville clinic to open Spring 2022 CHICAGO and TORONTO, March 11, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life…
read moreWesana’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a microdose of psilocybin combined with cannabidiol, significantly reduced…
read moreThe meeting is scheduled for March 11, 2022 CHICAGO and TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data driven…
read more
